Safety and efficacy of bakutrol^TM face cream in the treatment of facial acne

Acne is a chronic and recurring inflammatory skin disease. It remains one of the most disturbing skin conditions that adversely affect an individual’s daily life. The therapeutic targets for acne include excessive sebum production, follicular hyper-keratinization, bacterial colonization by P. acnes, and inflammation. Currently, retinoic acid is the only agent effective against all four targets of acne therapy. However, its several side effects limit its wide application. Bakutrol™ is a topical formulation containing 0.5% bakuchiol from Cullen corylifolium. (Psolarea corylifolia). Bakuchiol is a popular skin care cosmetic ingredient due to its retinol-like functionality. A prospective, open-label, single-arm study was conducted to evaluate the safety and efficacy of Bakutrol™ in patients (n=50) with facial acne. The participants were instructed to apply Bakutrol^TM cream as a thin layer over the acne lesions twice daily for 60 days. Key outcomes evaluated were safety and efficacy in controlling P. acnes infection. Application of Bakutrol^TM resulted in 36.14% reduction in P. acne bacterial load. Video-dermoscopy and photographic images showed the reduction of inflammatory lesions. Bakutrol^TM demonstrated an excellent safety profile as there were no adverse events seen during the study period. In summary, Bakutrol™ face- cream is a natural, safe, and effective treatment of facial acne. Its effect on both inflammatory and non-inflammatory lesions of acne makes it a promising agent for the treatment of acne and even for the post-inflammatory hyper-pigmentation in acne.